Pulmonx Corporation LUNG
1.91
0.01
0.53%
as of 25 Sep
- Market cap
- $81.6M
- P/E
- 0.0×
Follow LUNG
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (88.87%) | (86.22%) | (77.19%) | (73.73%) |
+8 more TTM periods Free account |
|
| (36.74%) | (39.31%) | (36.97%) | (37.13%) | ||
ROIC |
(141.03%) | (153.90%) | (158.98%) | (175.58%) | |
Return on Tangible Assets |
(69.12%) | (70.10%) | (64.41%) | (62.50%) | |
Average Days of Receivables |
51.12 | 44.64 | 48.69 | 54.94 | |
Free Cash Flow per Share |
(0.72) | (0.70) | (0.81) | (0.80) | |
Free Cash Flow |
(30.67) | (29.41) | (32.83) | (32.57) | |
Capital Expenditures |
(0.11) | (0.16) | (0.45) | (0.55) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(23.02%) | (20.20%) | (20.10%) | (18.41%) | |
Accounts Receivable Turnover |
6.21 | 7.14 | 7.18 | 7.20 | |
Accounts Payable Turnover |
3.57 | 5.60 | 6.04 | 4.45 | |
Inventory Turnover |
1.23 | 1.31 | 1.43 | 1.47 | |
Average Days of Payables |
85.05 | 58.42 | 61.02 | 95.74 | |
Days of Inventory on Hand |
298.18 | 274.29 | 247.60 | 242.30 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
22.14% | 22.17% | 21.54% | 20.63% | |
Selling, General and Administrative Expense of Revenue |
107.87% | 112.10% | 111.95% | 115.05% | |
Share Based Compensation of Revenue |
19.72% | 22.31% | 23.46% | 24.56% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.64 | 0.55 | 0.60 | 0.56 | |
Depreciation/Fixed assets |
0.57 | 0.44 | 0.33 | 0.18 | |
Capex/Depreciation |
(0.10) | (0.18) | (0.62) | (1.23) | |
Revenue per Share |
2.06 | 2.11 | 2.22 | 2.24 | |
Operating CF per Share |
(0.72) | (0.70) | (0.80) | (0.78) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | |
Net Profit Margin |
(55.03%) | (60.09%) | (59.67%) | (61.91%) |
Columns are period end dates